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IMPORTANCE To prevent blindness, repeated infant eye examinations are performed to
detect severe retinopathy of prematurity (ROP), yet only a small fraction of those screened
need treatment. Early individual risk stratification would improve screening timing and
efficiency and potentially reduce the risk of blindness.
OBJECTIVES To create and validate an easy-to-use prediction model using only birth
characteristics and to describe a continuous hazard function for ROP treatment.
DESIGN, SETTING, AND PARTICIPANTS In this retrospective cohort study, Swedish National
Patient Registry data from infants screened for ROP (born between January 1, 2007, and
August 7, 2018) were analyzed with Poisson regression for time-varying data (postnatal
age, gestational age [GA], sex, birth weight, and important interactions) to develop an
individualized predictive model for ROP treatment (called DIGIROP-Birth [Digital ROP]).
The model was validated internally and externally (in US and European cohorts) and
compared with 4 published prediction models.
MAIN OUTCOMES AND MEASURES The study outcome was ROP treatment. The measures
were estimated momentary and cumulative risks, hazard ratios with 95% CIs, area under the
receiver operating characteristic curve (hereinafter referred to as AUC), sensitivity, specificity,
positive predictive value (PPV), and negative predictive value (NPV).
RESULTS Among 7609 infants (54.6% boys; mean [SD] GA, 28.1 [2.1] weeks; mean [SD] birth
weight, 1119 [353] g), 442 (5.8%) were treated for ROP, including 142 (40.1%) treated of 354
born at less than 24 gestational weeks. Irrespective of GA, the risk for receiving ROP
treatment increased during postnatal weeks 8 through 12 and decreased thereafter.
Validations of DIGIROP-Birth for 24 to 30 weeks’ GA showed high predictive ability for the
model overall (AUC, 0.90 [95% CI, 0.89-0.92] for internal validation, 0.94 [95% CI,
0.90-0.98] for temporal validation, 0.87 [95% CI, 0.84-0.89] for US external validation,
and 0.90 [95% CI, 0.85-0.95] for European external validation) by calendar periods and by
race/ethnicity. The sensitivity, specificity, PPV, and NPV were numerically at least as high as
those obtained from CHOP-ROP (Children’s Hospital of Philadelphia–ROP), OMA-ROP
(Omaha-ROP), WINROP (weight, insulinlike growth factor 1, neonatal, ROP), and CO-ROP
(Colorado-ROP), models requiring more complex postnatal data.
CONCLUSIONS AND RELEVANCE This study validated an individualized prediction model for
infants born at 24 to 30 weeks’ GA, enabling early risk prediction of ROP treatment based
on birth characteristics data. Postnatal age rather than postmenstrual age was a better
predictive variable for the temporal risk of ROP treatment. The model is an accessible online
application that appears to be generalizable and to have at least as good test statistics
as other models requiring longitudinal neonatal data not always readily available to
ophthalmologists.
JAMA Ophthalmol. 2020;138(1):21-29. doi:10.1001/jamaophthalmol.2019.4502
Published online November 7, 2019.
Invited Commentary page 29
Supplemental content
Author Affiliations: Author
affiliations are listed at the end of this
article.
Corresponding Author: Ann





S-416 85 Gothenburg, Sweden
(ann.hellstrom@medfak.gu.se).
Research
JAMA Ophthalmology | Original Investigation
(Reprinted) 21
R etinopathy of prematurity (ROP) is a potentially blind-ing disease, and screening programs for detecting sight-threatening ROP needing treatment have been estab-
lished worldwide.1,2 Infants with lower gestational age (GA) have
a higher risk of sight-threatening ROP; in Sweden, the recom-
mendation is to screen infants with GA less than 31 weeks and
severely ill infants if older. Data are registered in the Swedish
National Registry for Retinopathy of Prematurity (SWEDROP).
Between 2008 and 2015, only 5.7% of screened infants in Swe-
den were treated for ROP.3 Screening includes retinal exami-
nations by specially trained ophthalmologists and is often stress-
ful for the infant4; without risk prediction, some infants may
not be screened and treated at the appropriate time. Individu-
alized risk estimates would allow for optimization of timing and
frequency of the screening processes from the health care and
economics perspectives. Improving the timing of screening vis-
its could avoid unnecessary examinations of low-risk infants and
optimize identification of those at high risk.
Risk and severity of ROP vary by prenatal and postnatal
factors,5 including poor prenatal and postnatal weight gain.
For this reason, the prediction algorithm WINROP (weight,
insulinlike growth factor 1, neonatal, ROP), which is based on
accumulated postnatal weight gain, has been validated and
broadly used.6-9 Similar tools based on longitudinal postna-
tal weight gain also have been developed.10-13 The objectives
of this study were to create, then to internally and externally
validate, and to describe the clinical implications of a predic-
tion model for individual momentary and cumulative risks
of ROP treatment based on birth characteristics alone, includ-
ing infants born at GA less than 31 weeks.
Methods
Study Population
Infants born between January 1, 2007, and August 7, 2018, at GA
less than 31 weeks and with completed ROP screening registered
in SWEDROP14 were included as part of the Swedish Neonatal
Quality Register,15 started in 2007, which has approximately 97%
coverage and contains perinatal data, screening outcomes, and
treatment information.3 All data are registered through standard-
ized protocols, in most settings by a trained pediatric ophthal-
mologist who has performed the screening examination. A vali-
dation of 85 randomly selected infants screened in 2018 showed
100% correctly reported values for variables used in this study.
This retrospective cohort study was approved by the ethics com-
mittee at Uppsala University, Uppsala, Sweden, who also waived
written informed consent because all the data were deidentified.
Model Development Group
In total, data for 8784 infants born between January 1, 2007,
and October 31, 2017, were retrieved from SWEDROP for the
prediction model development. Of those, data for 1372 of 8784
infants (15.6%) were excluded for having GA at least 31 weeks
at birth, and 126 of 8784 infants (1.4%) were excluded for miss-
ing data. This left 7286 of 8784 infants (82.9%) eligible for the
model development group. Of those, 6947 of 7286 infants
(95.3%) had GA 24 to 30 weeks (Figure 1).
Validation Groups
The group used for temporal validation consisted of infants
born between November 1, 2017, and August 7, 2018, and reg-
istered in SWEDROP. Among infants born at GA 24 to 30 weeks,
308 of 323 (95.4%) were eligible and served as the validation
temporal group (Figure 1).
The validation US group included 1485 of 1535 eligible in-
fants (96.7%) born at GA 24 to 30 weeks from 12 US centers be-
tween 2005 and 2010 (Figure 1).16 The validation European
group included 329 of 354 eligible infants (92.9%) born at GA
24 to 30 weeks from Freiburg, Germany, with retrospective
screening data collected between 2011 and 2017 (Figure 1).17
Study Procedures
The estimation of GA was based on fetal ultrasonographic re-
sults. The chronological (postnatal) age, postmenstrual age,
and GA are defined according to the American Academy of
Pediatrics’ issued policy.18 An SD score (SDS) of expected ref-
erence weight (birth weight SDS [BWSDS]) was calculated
based on GA, sex, and birth weight for all healthy singletons
born at GA at least 24 weeks between 1990 and 1999 in Swe-
den and registered in the Medical Birth Register (800 000
healthy infants of approximately 1 million born).19 Hence,
BWSDS was not calculated for infants born at GA less than 24
weeks because of a lack of reference for this extremely pre-
term population. Infants born at GA less than 24 weeks are at
high risk of severe ROP requiring treatment, partly owing to a
larger proportion of avascular retinal area at birth,20 and pre-
diction models are not as useful in this cohort. Therefore, a sim-
pler prediction model was developed for this group and is
presented along with the results in eAppendix 1 (which refer-
ences eFigures 9-11 and eTables 7 and 8) in the Supplement.
Small for GA19 was defined as BWSDS less than −2.
Study Outcome
The prediction model was developed to estimate risk for treat-
ment of sight-threatening ROP. The International Classifica-
tion of Retinopathy of Prematurity21 and Early Treatment for
Retinopathy of Prematurity (ETROP)22 criteria for treatment
were used.
Key Points
Question Can a prediction model be constructed for retinopathy
of prematurity needing treatment by using only birth
characteristics data and applying advanced statistical methods?
Findings In this cohort study of 6947 infants born at gestational
age 24 to 30 weeks, the prediction model incorporating only
postnatal age, gestational age, sex, and birth weight provided a
predictive ability for retinopathy of prematurity needing treatment
that was comparable to current models requiring postnatal data
(not always available). The risk for retinopathy of prematurity
needing treatment increased up to 12 weeks’ postnatal age
irrespective of the infants’ gestational age.
Meaning This prediction model identifying infants with a high risk
for developing sight-threatening disease at an early time may
improve the conditions for optimal screening.
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Statistical Analysis
General Methodology
Number and percentage are given for categorical variables; for
continuous variables, the mean, SD, median, range, and inter-
quartile range are provided, where applicable. For comparison
between 2 groups, we used the Fisher exact test for dichoto-
mous variables, Mantel-Haenszel χ2 trend test for ordered cat-
egorical variables, and Mann-Whitney test for continuous vari-
ables. The Jonckheere-Terpstra test was applied for identifying
trends between ordered categorical and continuous variables.
The crude week-specific risk of ROP treatment (number of in-
fants with the event divided by number of infants at risk) was
analyzed based on postnatal age and postmenstrual age (GA plus
postnatal age) by GA at birth. The modeling process consisted
of (1) prediction model development, (2) internal and external
validation, and (3) clinical implication.23 The prediction model
for ROP treatment, called DIGIROP-Birth (Digital ROP), was de-
veloped using Poisson regression for time-varying data, from
which we obtained a continuous hazard function, h(t), describ-
ing momentary risk for ROP treatment.24,25 From the hazard
function, the survival function
S(t) = e–∫0t h (u) du
and its complement, the cumulative risk function F(t) = 1 − S(t),
were estimated. The 95% CI for F(t) was obtained via repeated
sampling (1000 samples) of the model parameters from a mul-
tivariate normal distribution using a covariance matrix estimated
by the Poisson regression models. Parameter estimates, SEs, and
hazard ratios (HRs) with 95% CIs are presented. The predictive
ability of the continuous cumulative risks was checked and was
found to be similarly high after postnatal age 15 weeks (eFigure 1
in the Supplement). Given this information and the knowledge
about the studied hazard function, the cumulative risks of ever
needing ROP treatment during 20 postnatal weeks were used for
interpretation.
All tests above were 2-tailed and conducted at the .05 sig-
nificance level, with no adjustments for multiple compari-
sons. All analyses were performed using SAS statistical soft-
ware, version 9.4 (SAS Institute Inc).
DIGIROP-Birth Prediction Model for GA 24 to 30 Weeks
Development and Validation
Based on the crude risks for ROP treatment over time strati-
fied by GA, we found that postnatal age was the most appro-
priate time axis. The final model for GA 24 to 30 weeks in-
cluded the following: piecewise linear current postnatal age
(break points, 8 and 12 weeks), piecewise linear continuous GA
given in weeks and days (break point, 27 weeks), sex, piece-
wise linear BWSDS (break point, −1 SDS), postnatal age × piece-
wise linear GA interaction, sex × GA interaction, and postna-
tal age × piecewise linear BWSDS interaction. The break points
for the variables were selected based on graphical review of
univariable hazard functions. The final model was built by
gradually expanding the models, starting only with postnatal
age and further keeping interactions with P < .10.
Figure 1. Study Flowchart
9135 Total SWEDROP cohort 2007-2018
8784 Model development group
potential population 2007-2017
351 Validation temporal group
potential population 2017-2018
1498 Excluded
6 Inconsistency in dates
1372 GA ≥31 wk
14 No visit date
7 No follow-up data
1 Missing data on sex
98 Missing data on weight
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4 No visit date
8 Missing data on weight




1706 Validation US group potential
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471 Validation European group
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171 Excluded
169 GA ≥31 wk
2 Inconsistency in dates
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1 Missing data on ROP
110 GA ≥31 wk
5 Missing data on weight
1 Missing data on GA
50 GA <24 wk 1485 Validation
US group
GA ≥24 wk












GA indicates gestational age; ROP, retinopathy of prematurity; and SWEDROP, Swedish National Registry for Retinopathy of Prematurity.
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Internal, temporal, and geographical external validations
were performed. The model fit and adaptation were described by
the area under the receiver operating characteristic curve (here-
inafter referred to as AUC) overall, by calendar periods, and by
race/ethnicity.Weperformedcross-validationandevaluatedcali-
bration plots; calculated sensitivity, specificity, positive predic-
tive value (PPV), and negative predictive value (NPV); and com-
pared DIGIROP-Birth with 4 other published prediction models
(CHOP-ROP [Children’s Hospital of Philadelphia–ROP],11 OMA-
ROP [Omaha-ROP],12 WINROP [weight, insulinlike growth factor
1,neonatal,ROP],7 andCO-ROP[Colorado-ROP]13)usingGA,birth
weight, and different weight gain variables in the algorithms, as
described in more detail in eAppendix 2 in the Supplement.
Results
Study Population
Birth characteristics for the whole SWEDROP cohort, model
development group, and validation temporal group, as well as
by maximum ROP stage, are listed in eTable 1 in the Supple-
ment. Among 7609 patients, 4155 (54.6%) were boys, the mean
(SD) GA was 28.1 (2.1) weeks, and the mean (SD) birth weight
was 1119 [353] g. Of those born at GA at least 24 weeks, 1510 of
7255 (20.8%) were small for GA. In total, 354 of 7609 (4.7%)
were born at GA less than 24 weeks, and 2806 of 7609 (36.9%)
were born at GA 24 to less than 28 weeks. Birth characteris-
tics were numerically balanced between the model develop-
ment group and the validation temporal group. Birth charac-
teristics for the validation US group and the validation
European group are listed in eTable 2 in the Supplement.
ROP Treatment Incidence in Screened Infants
Altogether, 2427 of 7609 infants (31.9%) developed any ROP,
which regressed spontaneously in 1985 of 7609 (26.1%) and was
treatedin442of7609(5.8%)(eTable3intheSupplement).Among
infants with GA less than 24 weeks, 142 of 354 (40.1%) were
treated, 287 of 2806 (10.2%) among those with GA 24 to less than
28 weeks and 13 of 4449 (0.3%) among those with GA at least 28
weeks. The incidence of ROP treatment for infants born at GA 24
to 30 weeks was 125 of 1485 (8.4%) in the validation US group and
17 of 329 (5.2%) in the validation European group.
Momentary Individual Risk of ROP Treatment
for GA Less Than 31 Weeks
Figure 2A and B show crude week-specific risk of ROP treat-
ment for the SWEDROP population. Table 1 lists the observed
timing for ROP treatment applying postnatal age and post-
menstrual age as time axes. The ROP treatment risk peaked at
postnatal week 12 regardless of GA at birth, but no specific pat-
tern by GA was seen for postmenstrual age.
From the Poisson regression model based on the total
SWEDROP population, including postnatal age and adjusting
for GA, the risk for ROP treatment increased by 54% (HR, 1.54;
95% CI, 1.39-1.70) per week from postnatal weeks 8 through
12. Afterward, it decreased by 30% (HR, 0.70; 95% CI, 0.67-
0.74) per week (Figure 2C and eTable 4 in the Supplement).
Cumulative Individual Risk of ROP Treatment
for GA 24 to 30 Weeks
Table 2 summarizes the final DIGIROP-Birth model for ROP treat-
ment in infants born at GA 24 to 30 weeks. The estimated cu-
mulative risks were 60.0% and 35.1%, respectively, for a girl with
BWSDS −3 and 0 born at GA 24 weeks and were 27.8% and 14.2%,
respectively, if she was born at GA 25 weeks (Figure 3 and eFig-
ure 2 and eTable 5 in the Supplement). Corresponding figures
for a boy with the same background data were 57.7% and 33.4%,
respectively, and 32.5% and 16.9%, respectively. Greater de-
creasing risk was observed for girls than for boys with increas-
Figure 2. Crude Week-Specific and Momentary Individual Risk






























Postmenstrual Age to ROP Treatment, wk






























Postnatal Age to ROP Treatment, wk





























Postnatal Age to ROP Treatment, wk














Shown is risk for gestational age (GA) less than 31 weeks.
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ing GA (P for interaction = .02), with HRs of 0.83 (95% CI, 0.64-
1.07) at 25 weeks and 0.50 (95% CI, 0.33-0.76) at 27 weeks (crude
incidences are shown in eFigure 3 in the Supplement, and pre-
dicted cumulative risks are shown in eFigure 4 in the Supple-
ment). The cumulative risk estimates with 95% CIs are avail-
able online for public use,26 requiring input of GA in weeks and
days, sex, and birth weight for the infant.
Internal and External Validation of DIGIROP-Birth
for GA 24 to 30 Weeks
eFigure 5 in the Supplement shows AUCs from the internal and
external validations, indicating whether the model discrimi-
nates well between receiving or not receiving treatment. The
AUC for the model development group was 0.90 (95% CI, 0.89-
0.92), and the AUC for the cross-validation model was 0.90
(95% CI, 0.89-0.91). The AUCs for different calendar periods
ranged from 0.87 to 0.92. The calibration plots, examining
overestimation or underestimation of risks in different re-
gions, showed the model as being overall well adapted (eFig-
ure 6 in the Supplement). Temporal validation of DIGIROP-
Birth showed an AUC of 0.94 (95% CI, 0.90-0.98). Geographical
external validation resulted in an AUC of 0.87 (95% CI, 0.84-
0.89) for the validation US group and an AUC of 0.90 (95% CI,
0.85-0.95) for the validation European group. The AUCs for
Table 1. Comparison Between US Guidelines (Fierson et al2) Regarding Timing of Initial Examination vs SWEDROP Data and DIGIROP-Birth Model,
2007-2018
GA at Birth, wk





























21 NR 31 NA NA NR 10 NA NA
Mean (SD) NA NA 34.6 (1.7) NA NA NA 12.8 (1.7) NA
Median (range) NA NA 34.6 (33.4-35.9) NA NA NA 12.8 (11.6-14.0) NA
No./total No. NA NA 2/2 NA NA NA 2/2 NA
22 31 31 NA NA 9 9 NA NA
Mean (SD) NA NA 36.3 (3.2) NA NA NA 13.6 (3.2) NA
Median (range) NA NA 35.1 (32.6-47.1) NA NA NA 12.4 (10.0-24.3) NA
No./total No. NA NA 39/82 NA NA NA 39/82 NA
23 31 31 NA NA 8 8 NA NA
Mean (SD) NA NA 36.5 (2.9) NA NA NA 13.1 (2.8) NA
Median (range) NA NA 36.0 (32.9-51.4) NA NA NA 12.6 (9.4-28.3) NA
No./total No. NA NA 101/270 NA NA NA 101/270 NA
24 31 31 NA 30.2 7 7 NA 6.2
Mean (SD) NA NA 37.1 (2.5) NA NA NA 12.7 (2.5) NA
Median (range) NA NA 36.6 (32.4-45.7) NA NA NA 12.3 (8.3-21.4) NA
No./total No. NA NA 117/436 NA NA NA 117/436 NA
25 31 31 NA 31.7 6 6 NA 6.7
Mean (SD) NA NA 38.2 (2.9) NA NA NA 12.9 (2.9) NA
Median (range) NA NA 37.7 (33.1-47.0) NA NA NA 12.4 (7.4-21.9) NA
No./total No. NA NA 92/620 NA NA NA 92/620 NA
26 31 32 NA 33.2 5 6 NA 7.2
Mean (SD) NA NA 39.7 (3.3) NA NA NA 13.3 (3.3) NA
Median (range) NA NA 39.3 (33.1-52.1) NA NA NA 13.0 (7.0-25.6) NA
No./total No. NA NA 58/801 NA NA NA 58/801 NA
27 31 33 NA 34.7 4 6 NA 7.7
Mean (SD) NA NA 40.3 (2.8) NA NA NA 12.9 (2.9) NA
Median (range) NA NA 40.1 (35.7-45.3) NA NA NA 12.6 (7.9-17.7) NA
No./total No. NA NA 20/949 NA NA NA 20/949 NA
28 32 34 NA 35.7 4 6 NA 7.7
Mean (SD) NA NA 40.8 (3.8) NA NA NA 12.4 (3.9) NA
Median (range) NA NA 39.4 (36.1-47.7) NA NA NA 11.1 (7.6-18.9) NA
No./total No. NA NA 10/1179 NA NA NA 10/1179 NA
29 33 36 NA 37.3 4 7 NA 8.1
Mean (SD) NA NA 39.7 (2.2) NA NA NA 10.1 (2.3) NA
Median (range) NA NA 39.4 (37.6-42.0) NA NA NA 9.7 (8.0-12.6) NA
No./total No. NA NA 3/1479 NA NA NA 3/1479 NA
30 34 37 NA 38.8 4 7 NA 8.7
No./total No. NA NA 0/1791 NA NA NA 0/1791 NA
Abbreviations: DIGIROP, Digital ROP; GA, gestational age; NA, not applicable;
NR, not reported; ROP, retinopathy of prematurity; SWEDROP, Swedish
National Registry for Retinopathy of Prematurity.
a Suggested age defined as integer value of the minimum time to ROP
treatment subtracted by 1 week for safety reasons.
b Given the SWEDROP population, DIGIROP-Birth model for GA 24 to 30 weeks,
with its sex and birth weight SD score distribution.
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stratified analysis on race/ethnicity categories in the valida-
tion US group were 0.79 for Hispanic infants, 0.85 for Asian
infants, 0.86 for non-Hispanic infants, 0.88 for white infants,
and 0.90 for black infants.
DIGIROP-Birth for GA 24 to 30 Weeks vs Existing ROP
Models (Requiring Postnatal Longitudinal Data)
The comparisons of DIGIROP-Birth vs CHOP-ROP, OMA-ROP,
WINROP, and CO-ROP were performed on the validation US
group, enabling the use of longitudinal weight data. These re-
sults are summarized in eFigures 7 and 8 and eTable 6 in the
Supplement.
Applying the CHOP-ROP algorithm (AUC, 0.89; 95% CI,
0.87-0.92) and categorizing the probabilities based on the rec-
ommended cutoff of 0.0140, similar prediction ability was ob-
served compared with DIGIROP-Birth (AUC, 0.88; 95% CI, 0.86-
0.91), and a cutoff of 0.0083 obtained the same sensitivity (95
of 96 [99.0%] for both CHOP-ROP and DIGIROP-Birth. Speci-
ficity was 598 of 1346 (44.4%) vs 658 of 1346 (48.9%), respec-
tively. Applying the same cutoff on the complete SWEDROP
database, the model showed 97.7% (95% CI, 95.3%-99.1%) sen-
sitivity and 59.5% (95% CI, 58.4%-60.7%) specificity. Apply-
ing a cutoff of 0.00083 for 100% (95% CI, 98.8%-100%)
sensitivity in the cohort, a specificity of 19.0% (95% CI, 18.1%-
20.0%) was obtained.
Compared with OMA-ROP (AUC, 0.77; 95% CI, 0.72-
0.82), a cutoff of 23 g per day in weight gain, with a corre-
sponding cutoff of 0.0200 for DIGIROP-Birth (AUC, 0.90; 95%
CI, 0.87-0.92), a sensitivity of 90 of 92 (97.8%) was obtained.
Specificity was 173 of 771 (22.4%) for OMA-ROP vs 448 of 771
(58.1%) for DIGIROP-Birth.
Compared with WINROP (AUC, 0.81; 95% CI, 0.78-0.84),
the alarm category of WINROP score 2 or 3 provided a sensi-
tivity of 121 of 125 (96.8%), with a corresponding cutoff of
0.0089 for DIGIROP-Birth (AUC, 0.87; 95% CI, 0.84-0.89).
Specificity was 487 of 1360 (35.8%) for WINROP vs 671 of 1360
(49.3%) for DIGIROP-Birth.
The specificity was 141 of 1341 (10.5%) for the CO-ROP
algorithm and 642 of 1341 (47.9%) for DIGIROP-Birth. Both had
a sensitivity of 122 of 124 (98.4%).
Clinical Practice Implications of DIGIROP-Birth
for GA 24 to 30 Weeks
Based on ROP treatment timing in the SWEDROP cohort (2007-
2018) and the DIGIROP-Birth model, we compared the re-
sults with the current US recommendations, based on stud-
ies that are more than 20 years old,2 for postnatal age and
postmenstrual age at initial examination (Table 1). The maxi-
mum age for estimated risk less than 0.001 corresponds well
to the observed minimum age for ROP treatment, except for
GA 24 weeks, for which a somewhat higher risk at a younger
age was estimated. Recommending that the initial examina-
tion should start 1 week before the earliest observed ROP treat-
ment per GA week in our cohort would potentially have avoided
14 867 of 135 061 visits (11.0%), assuming 1 visit per week. For
GA of at least 27 weeks, with a ROP treatment incidence of 33
of 5398 (0.6%), the difference between the US recommenda-
tions and this study resulted in 14 066 of 93 052 examina-
tions (15.1%) potentially being avoided.
Discussion
We have created and validated the DIGIROP-Birth prediction
model, available free of charge online26 based on 6947 infants
born at GA 24 to 30 weeks, estimating the individual momen-
tary and cumulative risks for ROP treatment. The model using
only available data at birth but more advanced statistical meth-
Table 2. Final Prediction Analysis Model for Retinopathy of Prematurity
Treatment for Infants Born at GA of 24 to 30 Weeks Using Poisson
Regression for Time-Varying Data
Predictor Estimate (SE) P Value
Intercept −20.1666 (4.9219) <.001
Postnatal age 0 to 8 wk, per 1-wk increase 1.7331 (0.6129) .005
Postnatal age >8 to 12 wk,
per 1-wk increase
0.3618 (0.0992) <.001
Postnatal age >12 wk, per 1-wk increase −0.3788 (0.0857) <.001
GA 24-27 wk, per 1-wk increase −0.8210 (0.3353) .01
GA >27 wk, per 1-wk increase 0.7266 (0.7302) .32
Sex, 1 = boys, 2 = girls −0.9385 (0.3054) .002
BWSDS −1 SDS or less, per 1-SDS increase 0.1521 (0.2656) .57
BWSDS exceeding −1 SDS,
per 1-SDS increase
−1.0401 (0.4710) .03
INT: postnatal age in weeks
by GA 24-27 wk, per 1-wk increase
0.0227 (0.0230) .32
INT: postnatal age in weeks
by GA >27 wk, per 1-wk increase
−0.1360 (0.0627) .03
INT: sex by GA, per 1-wk increase −0.2505 (0.1066) .02
INT: postnatal age in weeks
by BWSDS −1 SDS or less
−0.0371 (0.0199) .06
INT: postnatal age in weeks
by BWSDS exceeding −1 SDS
0.0728 (0.0349) .04
Abbreviations: BWSDS, birth weight standard deviation score; GA, gestational
age; INT, interaction term; SDS, SD score.

























GA at Birth, wk
30292827262524
Boy BWSDS = –3
Boy BWSDS = 0
Girl BWSDS = –3
Girl BWSDS = 0
Shown is cumulative risk (95% CI) by gestational age (GA) 24 to 30 weeks
for boys and girls born with birth weight SD score (BWSDS) −3 and 0.
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ods was at least as accurate as 4 of the ROP prediction models
now in use based on longitudinal weight measurements, which
are not always readily available to ophthalmologists.
Surprisingly, the momentary risk of ROP treatment peaked
at 12 weeks’ postnatal age regardless of GA at birth, while no
specific pattern was observed for postmenstrual age. This ob-
servation is particularly interesting because the ETROP study27
found that the progression of prethreshold ROP was highly
associated with postmenstrual age, similar to the finding in the
CRYO-ROP (Cryotherapy for ROP) study28 15 years earlier. How-
ever, it should be emphasized that infants included in the
CRYO-ROP study were born at higher GA, and no GA-specific
hazard functions were studied for ROP outcome. Other Swed-
ish studies29,30 have reported that lower GA at birth is associ-
ated with lower GA at treatment, but the momentary risk in
relation to postnatal age and postmenstrual age was not ana-
lyzed. Recently, in a large North American cohort, the timing
of ROP treatment was presented only in relation to postmen-
strual age and not postnatal age.31
The identification of a peak risk at 12 postnatal weeks in
infants with GA less than 31 weeks might be clinically useful
because it was recently shown that inadequate screening or
treatment was identified in 11 of 17 cases with blindness from
ROP (64.7%).32 Hence, clinicians and parents could be alerted
during this period to ensure that timely screening occurs to
reduce the risk of blindness.
National patient registries are valuable sources for esti-
mation of treatment risks. Herein, the DIGIROP-Birth model
was compared with a validation US group and a validation
European group and showed high predictive ability and gen-
eralizability both for individuals with the same and with dif-
ferent reported race/ethnicity.
The ROP prediction models may also be used to reduce
screening frequency in infants at low risk. The latest US policy
statement for ROP screening2 was issued in 2018. The recom-
mendations for the timing of the first examination were based
on the CRYO-ROP study28 published in 1991 and the LIGHT-ROP
(Light Reduction in ROP) study33 published in 1998. In those pe-
riods, fewer extremely preterm infants survived, more mature
infants were treated, and treatment criteria were different from
those used today. Based on the results of our study, if the initial
examination was performed 1 week before the earliest observed
postnatal age at ROP treatment, 14 867 of 135 061 stressful early
examinations (11.0%) could be avoided (assuming 1 examina-
tion per week) compared with US recommendations.2 For GA
of at least 27 weeks, with a ROP treatment incidence herein less
than 1%, 14 066 of 93 052 examinations (15.1%) could have been
avoided while capturing all cases of ROP treatment (100% sen-
sitivity). Notably, reaching 100% sensitivity in such models of
real-life, large data sets is accompanied by low specificity. Based
on approximately as large a cohort as in our study, the updated
CHOP-ROP11 model, which uses longitudinal weight data and
birth data, achieved 11.2% specificity for 100% sensitivity and
36.4% specificity for 98.5% sensitivity; DIGIROP-Birth (using
only readily obtained birth data) showed 19.0% specificity for
100% sensitivity and 53.8% specificity for 99.0% sensitivity.
Strengths and Limitations
The strengths of our study include the unique and complete
cohort of preterm infants born in Sweden between January
2007 and August 2018. Also, our statistical model includes 3
basic measurements (GA, sex, and birth weight). The postna-
tal age for ROP treatment or censoring (discontinued follow-
up) is included in the hazard function estimation but is not re-
quired as an input variable. Hence, the input data are simple,
facilitating their general use, even though the method is more
advanced, taking into account the underlying hazard func-
tion and the important interactions that contribute to adjust-
ment of heterogeneity, which is novel in ROP research. The
DIGIROP-Birth has shown strong predictive ability in inter-
nal, temporal, and geographical external validations. If found
not acceptable in future validations among a population, a sub-
group-specific model designed for optimal predictions in that
population might be developed using our methods. Finally,
DIGIROP-Birth has been shown to be equal to or better than 4
other ROP prediction models and is accessible online.26
Our study has some limitations. One limitation is the use
of registry retrospective data. However, the registry showed
high coverage and successful validation of data for 85 ran-
domly selected infants screened in 2018. In addition, infants
born at GA less than 24 weeks could not be included in the pre-
diction model because of the lack of a reference algorithm for
birth weight, preventing BWSDS calculations. Given the small
sample size, only a simple model could be developed for these
infants, resulting in low predictive ability. Close monitoring of
such infants is mandatory irrespective of calculated risk, mak-
ing prediction models less important for this group.
Conclusions
We created and validated the DIGIROP-Birth model, an indi-
vidualized early prediction model for infants with GA 24 to
30 weeks, which estimates momentary and cumulative risks
for receiving ROP treatment based on simple birth character-
istics. A surprising finding was that postnatal age was the
best predictive variable for the temporal risk of ROP treat-
ment. The DIGIROP-Birth model is an accessible online
application that appears to be generalizable and to have at
least as good test statistics as other models that require lon-
gitudinal neonatal data, which are not always readily avail-
able to ophthalmologists.
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Invited Commentary
A Prediction Model for Retinopathy of Prematurity—
Is It Ready for Prime Time?
Gui-shuang Ying, PhD
Retinopathy of prematurity (ROP), the leading cause of pre-
ventable childhood blindness worldwide, is traditionally de-
tected by eye examinations performed by ophthalmologists
on infants at risk for ROP.
Because of the low diagnos-
tic yield of these examina-
tions for identifying infants
that require treatment of ROP, various statistical prediction mod-
els have been developed to identify infants at high ROP risk who
require frequent eye examinations and infants at low risk who
require less-frequent or no ROP examinations.1 These predic-
tion models use statistical modeling approaches of various com-
plexity, usually including birth weight (BW), gestational age (GA),
and postnatal factors, such as oxygen exposure or postnatal
weight gain. The model performance is usually evaluated using
sensitivity, specificity, or the reduction in number of infants ex-
amined for detecting the ROP outcome of interest (eg, severe
ROP, ROP requiring treatment, type 1 ROP). Most prediction
models were developed from a small numbers of infants who
have the ROP outcomes of interest, potentially leading to over-
fitting or optimistic estimates of model performance. When ap-
plying prediction models to an independent cohort through ex-
ternal validation, their performance usually becomes poorer.
Because no prediction model works well universally, research
on developing and validating robust ROP prediction models for
clinical use continues to be of interest.
In this issue of JAMA Ophthalmology, Pivodic et al2
developed and validated an individual risk prediction model
(DIGIROP-Birth) for identifying ROP requiring treatment
using purely birth characteristics (BW, GA, and sex), without
consideration of any postnatal factors. The prediction model
was developed based on 7286 infants born prematurely who
were listed in the Swedish National Patient Registry and
screened for ROP from 2007 to 2017. In Sweden, infants with
GAs less than 31 weeks or severe illness were registered for
ROP screening (with an approximate 97% coverage rate). In
the model development cohort, the model had an area under
receiver operating characteristic curve (AUC) of 0.90. When
the model was externally validated in a new cohort in Swe-
den (n = 323), a US cohort (n = 1535), and an European
cohort (n = 354), the AUC remained similarly high (0.94 for
the Swedish cohort, 0.87 for the US cohort, and 0.90 for the
European cohort). Furthermore, when the DIGIROP-Birth
model was compared with a few existing prediction models
that require postnatal factors (the Children’s Hospital of
Philadelphia–ROP, Omaha–ROP, Colorado–ROP, and weight,
insulinlike growth factor I, neonatal ROP models) in a US
cohort, this model suggested higher specificity than other
models at the same high sensitivity (≥96.8%). However, this
model was not compared with a recently developed3 and
externally validated Growth and Retinopathy of Prematurity
(G-ROP) modified screening criteria.4,5 The G-ROP screening,
developed from a large representative cohort of 7483 infants
at risk in North America, requires that infants undergo ROP
examination if any of 6 criteria are met: (1) a GA smaller than
28 weeks, (2) a BW less than 1051 g, (3) weight gain less
than 120 g during days of life 10 to 19, (4) weight gain
less than 180 g during days of life 20 to 29, (5) weight gain
less than 170 g during days of life 30 to 39, or (6) the pres-
ence of hydrocephalus. The G-ROP criteria resulted in the
correct identification of all cases of type 1 ROP and reduced
the number of infants who required ROP examinations by
30%.3 Similar performance outcomes were found in a large
prospective validation cohort.5
There are several strengths of the DIGIROP-Birth model.
First, this model was developed from a large cohort with a large
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